Clinical trials: PET Imaging in Patients With Prostate Cancer
Prostatic Neoplasms, Prostate Cancer
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
This study aims to evaluate the diagnostic performance of [68Ga]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected…
- Trial name
- NCT07830212
- Testing
- [68Ga]Ga-OncoACP3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yong He
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04927663
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
Prostate Hypoxia FAZA
The purpose of this study is to look for low levels of oxygen (hypoxia) in prostate cancer using a special x-ray test called a positron emission tomography (PET)scan.
- Trial name
- NCT01567800
- Testing
- 18F-Fluoroazomycin Arabinoside (18F-FAZA)
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
PET Scan in Treating Patients With Metastatic Prostate Cancer
RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.
- Trial name
- NCT00002981
- Testing
- positron emission tomography, fludeoxyglucose F 18, methionine C 11
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
- Trial name
- NCT07649122
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 232 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostatic Neoplasms
Prostate Hyperfixation on PET-choline in Patients With Prostate Cancer: Correlation With MRI and Pathological Data (LOC-CHOLINE)
In France, when prostate cancer is suspected, multiparametric MRI is the reference imaging technique for tumor localization, and is used to guide biopsies in order to characterize the tumor as accurately as possible.
- Trial name
- LOC-CHOLINE (NCT06836154)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Brest
Prostate Cancer, Localized Prostate Cancer
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for [18F] Dihydro-Testosterone), to better find and monitor prostate cancer.
- Trial name
- NCT02297386
- Testing
- [18F] DIHYDRO-TESTOSTERONE, PET scan, MRI
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer Screening, PSMA-PET
PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy
The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing…
- Trial name
- NCT06923657
- Testing
- PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy, TRUS guided transperineal saturation biopsy
- Where
- China
- Volunteers
- 230 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer
11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable…
- Trial name
- NCT02397408
- Testing
- Carbon C 11 Choline, Fluorine F 18 Choline, Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Prostatic Neoplasms, Prostate Cancer
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT07285057
- Testing
- rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with at least intermediate risk prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06011304
- Testing
- [18F]Florastamin Injection
- Where
- China
- Volunteers
- 287 people
- Sponsor
- HTA Co., Ltd.
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Carcinoma
Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer.
- Trial name
- MSG PSMA PET (NCT04282824)
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
The aim of this study is to investigate safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 for detection and localization of primary prostate cancer confirmed by histopathology of the prostate as a…
- Trial name
- NCT02483884
- Testing
- [68Ga]RM2, PET/CT
- Where
- 2 sites in Austria, Finland
- Volunteers
- 30 people
- Sponsor
- Lantheus Biosciences Ltd.
Prostate Cancer
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
- Trial name
- NCT06122584
- Testing
- [18F]PSMA-1007
- Where
- 18 sites in France, Germany and 4 more
- Volunteers
- 380 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Prostate Cancer
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy…
- Trial name
- NCT03353740
- Testing
- Ga-68 labeled PSMA-11 PET
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Thomas Hope
Prostate Cancer
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer.
- Trial name
- PRIDE2-PC (NCT07568613)
- Testing
- MRI, 18F-PSMA1007 PET-CT, MR-guided TRUS Prostate biopsy
- Where
- Cyprus
- Volunteers
- 50 people
- Sponsor
- German Oncology Center, Cyprus
Biochemical Recurrence of Malignant Neoplasm of Prostate
A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET
The REFINE study is evaluating whether a fluciclovine (18F) PET/CT scan can detect recurrent prostate cancer in patients whose previous PSMA PET/CT was negative or inconclusive.
- Trial name
- REFINE (NCT06859203)
- Where
- 2 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Technical University of Munich
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.